{"schema_version":"secwatch.filing_event.v1","accession":"0001326732-24-000059","form_type":"8-K","ticker":"XNCR","cik":"0001326732","company_name":"Xencor Inc","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.119586+00:00","generated_at":"2026-05-30T04:23:33.469241+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xencor Q3 net loss $45.1M ($0.71 EPS), revenue down 82% YoY; cash $754M","bullets":["Net loss of $45.1M ($0.71 diluted EPS) vs net loss of $24.3M ($0.40) in Q3 2023.","Revenue of $10.7M, down 82% YoY from $59.2M, driven by lower milestone and royalty revenue.","Cash and marketable securities $754.3M as of Sept 30, 2024, up from $697M at Dec 31, 2023; includes $189.2M net proceeds from September public offering.","Program updates: XmAb942 Phase 1 started; plamotamab Phase 1b/2a in RA planned H1 2025; XmAb808 DLTs in highest dose cohort.","Amgen's xaluritamig advancing to Phase 3 in mCRPC; Xencor expects 2024 year-end cash $690-710M, funding into 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001326732-24-000059","json":"https://secwatch.observer/filing/0001326732-24-000059.json","markdown":"https://secwatch.observer/filing/0001326732-24-000059.md","text":"https://secwatch.observer/filing/0001326732-24-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326732/000132673224000059/0001326732-24-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326732/000132673224000059/xncr-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:23:33.469241+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}